Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Activity of the oral MEK inhibitor trametinib in patients... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
0
Authors
Gerald Falchook
23 more
Gerald Falchook
•
Vijay Peddareddigari
21 more
•
Leslie Fecher
Published
July 15, 2012
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to review
Share your thoughts on this paper...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Biology
Cancer Oncology
Medicine
Internal Medicine
Molecular Biology
Show all topics
DOI
10.1016/s1470-2045(12)70269-3
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Biology
Cancer Oncology
Medicine
Internal Medicine
Molecular Biology
Show all topics
DOI
10.1016/s1470-2045(12)70269-3
Other Formats
PDF
